Research Article
Adherence to Methotrexate in Rheumatoid Arthritis: A Danish Nationwide Cohort Study
Table 3
Risk of nonadherence to MTX: Cox proportional hazard model; crude and multiply adjusted hazard rates (HR) and 95% confidence intervals (CI).
| | Variables at baseline | 5 mg per week | 7.5 mg per week | 5 mg per week# | 7.5 mg per week# | | Crude OR (95% CI) | Crude OR (95% CI) | HR (95% CI) | HR (95% CI) |
| | Gender (F/M) | 1.21 (1.13–1.30) | 1.18 (1.11–1.26) | 1.12 (1.06–1.19) | 1.07 (1.01–1.12) | | NSAID within last year | 1.09 (1.01–1.16) | 1.08 (1.01–1.15) | 1.03 (0.97–1.09) | 1.01 (0.96–1.06) | | Prednisolone within last year | 0.91 (0.86–0.97) | 0.93 (0.88–0.98) | 0.99 (0.94–1.04) | 1.00 (0.96–1.04) | | Biological antirheumatic therapy | 0.74 (0.24–2.32) | 1.48 (0.54–4.07) | 0.65 (0.24–1.73) | 1.04 (0.52–2.09) | | AMI | 0.90 (0.77–1.05) | 0.85 (0.73–0.98) | 1.07 (0.93–1.22) | 1.01 (0.90–1.14) | | Cerebrovascular events | 0.94 (0.82–1.08) | 0.95 (0.84–1.09) | 1.11 (0.99–1.25) | 1.14 (1.03–1.26) | | Dementia | 0.77 (0.47–1.26) | 1.01 (0.65–1.57) | 1.14 (0.75–1.74) | 1.46 (1.05–2.02) | | T1D with complications | 1.07 (0.79–1.45) | 1.01 (0.75–1.35) | 0.97 (0.71–1.33) | 0.92 (0.69–1.21) | | T2D with complications | 1.29 (1.01–1.65) | 1.26 (0.99–1.59) | 1.34 (1.07–1.68) | 1.30 (1.06–1.58) | | T1D | 1.06 (0.84–1.33) | 1.05 (0.84–1.31) | 0.93 (0.72–1.19) | 0.96 (0.78–1.19) | | T2D | 1.05 (0.90–1.23) | 1.08 (0.93–1.25) | 1.06 (0.91–1.24) | 1.10 (0.96–1.25) | | Hemiplegia | 1.36 (0.66–2.81) | 1.14 (0.56–2.33) | 1.45 (0.82–2.57) | 1.33 (0.78–2.24) | | Heart failure | 0.91 (0.77–1.08) | 0.94 (0.81–1.10) | 1.12 (0.97–1.29) | 1.20 (1.06–1.36) | | Atherosclerosis | 0.93 (0.79–1.09) | 1.01 (0.86–1.17) | 1.12 (0.97–1.28) | 1.23 (1.10–1.39) | | COPD | 1.10 (0.98–1.22) | 1.03 (0.93–1.14) | 1.23 (1.12–1.35) | 1.21 (1.11–1.31) | | Leukemia | 0.65 (0.28–1.51) | 1.06 (0.51–2.20) | 0.85 (0.41–1.79) | 1.37 (0.80–2.37) | | Lymphoma | 0.93 (0.61–1.42) | 0.96 (0.64–1.43) | 1.03 (0.72–1.47) | 1.05 (0.77–1.42) | | Metastatic malignancy | 0.62 (0.39–0.99) | 0.60 (0.39–0.92) | 0.85 (0.57–1.29) | 0.90 (0.63–1.28) | | Mild liver disease | 1.35 (1.02–1.78) | 1.25 (0.95–1.65) | 1.30 (1.05–1.63) | 1.28 (1.05–1.56) | | Moderate liver disease | 0.65 (0.28–1.51) | 0.68 (0.32–1.46) | 0.70 (0.33–1.47) | 0.76 (0.41–1.42) | | Kidney disease | 1.39 (1.11–1.73) | 1.30 (1.04–1.61) | 1.35 (1.14–1.61) | 1.31 (1.12–1.53) | | Solid cancer | 0.91 (0.75–1.11) | 0.85 (0.71–1.03) | 1.05 (0.89–1.24) | 1.00 (0.86–1.16) | | Ulcer disease | 0.94 (0.83–1.06) | 0.96 (0.85–1.07) | 1.07 (0.96–1.18) | 1.08 (0.98–1.18) | | Age | | | | | | <50 years | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | | 50–59 years | 0.79 (0.72–0.86) | 0.76 (0.70–0.82) | 0.84 (0.79–0.90) | 0.83 (0.78–0.88) | | 60–69 years | 0.59 (0.55–0.65) | 0.58 (0.53–0.63) | 0.70 (0.66–0.76) | 0.73 (0.69–0.78) | | ≥70 years | 0.59 (0.54–0.64) | 0.61 (0.56–0.66) | 0.77 (0.72–0.83) | 0.89 (0.83–0.95) | | Private practising rheumatologist | 0.95 (0.89–1.03) | 0.99 (0.92–1.06) | 0.97 (0.92–1.03) | 1.02 (0.97–1.07) | | Difference from diagnosis to MTX | | | | | | <0.5 years | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | | 0.5–0.99 years | 0.69 (0.64–0.75) | 0.74 (0.69–0.80) | 0.74 (0.69–0.79) | 0.80 (0.76–0.85) | | ≥1 year | 1.07 (1.00–1.15) | 1.02 (0.96–1.09) | 1.17 (1.11–1.24) | 1.21 (1.15–1.27) |
|
|
F: female; M: male; AIDS: acquired immune-deficiency syndrome; AMI: acute myocardial infarction; T1D: type 1 diabetes; COPD: chronic obstructive pulmonary disease.
#Mutually adjusted for the other variables in the table (Cox proportional hazard regression).
< 0.05.
|
